Nanoparticles Overcome Anticancer Drug Resistance

Jun 12, 2006

Too often, chemotherapy fails to cure cancer because some tumor cells develop resistance to multiple anticancer drugs. In most cases, resistance develops when cancer cells begin expressing a protein, known as p-glycoprotein, that is capable of pumping anticancer drugs out of a cell as quickly as they cross through the cell’s outer membrane. New research from the University of Kentucky shows that nanoparticles may be able to get anticancer drugs into cells without triggering the p-glycoprotein pump.

Writing in the Journal of Controlled Release, a team led by Russell Mumper, Ph.D., describes its work using untargeted nanoparticles made of cetyl alcohol and polysorbate, which the investigators have named E78 nanoparticles, as a delivery vehicle for the potent anticancer drug paclitaxel. Biodistribution studies with the formulation and with free paclitaxel revealed few significant differences in which the active drug ends up in the body.

Next, the investigators injected the nanoparticle-entrapped paclitaxel, empty nanoparticles, free paclitaxel, or saline directly into paclitaxel-resistant human colon tumors growing in mice. Nineteen days after injection, tumors in the animals treated with nanoparticle-entrapped paclitaxel were 47 percent smaller than those treated with free paclitaxel and 70 percent smaller than those in animals treated with plain nanoparticles or saline.

One surprising finding from this study was the fact that free paclitaxel had any effect at all on tumors known to be resistant to the drug. Further investigation showed that this effect was likely a result of paclitaxel’s ability to inhibit angiogenesis. The researchers concluded that nanoparticulate-entrapped paclitaxel was able to suppress tumor growth by killing tumor cells directly and through inhibition of angiogenesis.

This work is detailed in a paper titled, “In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors.” Based in part on these results, the NCI is now funding further work with a tumor-targeted version of this nanoparticle to determine if it can be used to overcome drug resistance in breast cancer patients. An abstract of this paper is available through PubMed.

Source: National Cancer Institute

Explore further: Gold nanorods target cancer cells

add to favorites email to friend print save as pdf

Related Stories

Gold nanoparticles: A new delivery for cancer drugs

May 08, 2013

(Phys.org) —The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer ...

Improved nanoparticles deliver drugs into brain

Sep 11, 2012

The brain is a notoriously difficult organ to treat, but Johns Hopkins researchers report they are one step closer to having a drug-delivery system flexible enough to overcome some key challenges posed by ...

Nanoparticles may enhance cancer therapy

Feb 16, 2012

A mixture of current drugs and carbon nanoparticles shows potential to enhance treatment for head-and-neck cancers, especially when combined with radiation therapy, according to new research by Rice University ...

Recommended for you

Gold nanorods target cancer cells

Dec 18, 2014

Using tiny gold nanorods, researchers at Swinburne University of Technology have demonstrated a potential breakthrough in cancer therapy.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.